Endotoxin Testing for Inhalation Products: Managing Contamination Risks, Formulation Interference, and Quality Control

Introduction: Why Endotoxin Control Matters in Inhalation Product Development

Inhalation drug products are designed to deliver active ingredients to the respiratory tract. Depending on the formulation and delivery system, these products may be administered as nebulized solutions, suspensions, metered-dose aerosols, or dry powders.

Their formulation and manufacturing requirements differ from those of many conventional oral and injectable medicines. Product performance depends not only on the active pharmaceutical ingredient (API), but also on formulation composition, aerosol characteristics, device compatibility, and the consistency of manufacturing processes.

Endotoxin control deserves careful consideration within this broader quality framework.

Bacterial endotoxins are lipopolysaccharide-containing components associated primarily with the outer membrane of Gram-negative bacteria. They may enter pharmaceutical materials through water, raw materials, equipment, containers, or manufacturing operations. Importantly, removing viable bacteria does not necessarily eliminate endotoxins that are already present.

For inhalation products, the appropriate endotoxin testing strategy depends on the specific product, its intended use, formulation, applicable regulatory expectations, and the risks associated with its manufacturing process. Requirements for injectable products should not automatically be applied to inhalation products without a scientific and regulatory justification.

Analytical testing also presents practical challenges. Inhalation formulations may contain surfactants, preservatives, salts, buffers, suspended particles, or other ingredients that affect assay performance. A method that works well for a simple aqueous sample may not perform equivalently with a complex respiratory formulation.

This guide examines potential endotoxin sources in inhalation product manufacturing, explains common analytical challenges, and outlines practical considerations for selecting and evaluating a bacterial endotoxin test.

1. Understanding the Different Types of Inhalation Products

The term “inhalation product” covers several dosage forms. Their physical characteristics and manufacturing processes can influence how endotoxin risks should be assessed.

Nebulizer solutions

Nebulizer solutions are liquid formulations converted into an inhalable aerosol by a nebulizer. Depending on the product, they may contain an API, water, buffers, tonicity-adjusting agents, preservatives, or other excipients.

Because water is a major component of many nebulizer solutions, water quality and the control of aqueous manufacturing systems can be important parts of the contamination-control strategy.

A clear solution is not necessarily free of endotoxin. Visual appearance provides no reliable indication of the endotoxin concentration.

Nebulizer suspensions

Suspensions contain dispersed solid particles rather than a fully dissolved active ingredient. Their particulate characteristics may complicate sample handling and analytical measurements.

Before testing, laboratories should consider whether the sample can be mixed consistently, whether representative aliquots can be obtained, and whether the formulation affects the selected assay.

The preparation procedure should preserve the representativeness of the sample without introducing contamination or changing endotoxin detectability.

Metered-dose inhalers and dry powder inhalers

Pressurized metered-dose inhalers and dry powder inhalers have different formulation and delivery characteristics from aqueous nebulizer products.

Their materials may include propellants, carrier particles, powders, device components, and specialized excipients. The relevant quality-control strategy should reflect the actual product and manufacturing process.

For dry powders, for example, sample extraction may be necessary before an aqueous endotoxin assay can be performed. The extraction procedure itself must be evaluated to determine whether it introduces interference or affects endotoxin recovery.

The physical form of a product therefore influences sample preparation, but it does not eliminate the need to evaluate whether endotoxin testing is appropriate.

2. Potential Sources of Endotoxin in Inhalation Product Manufacturing

A useful endotoxin-control strategy begins with identifying where contamination could enter the process.

Water and aqueous processing

Water may be used in formulation, equipment cleaning, intermediate preparation, and laboratory testing. If a water system is not adequately controlled, Gram-negative bacteria may proliferate under suitable conditions and contribute endotoxin to the system.

Potential risk points include:

• Water storage and distribution systems

• Stagnant sections of piping

• Transfer hoses and connections

• Preparation vessels

• Inadequately controlled cleaning operations

• Water used for formulation or dilution

Microbiological testing and endotoxin testing provide different information. A low viable microbial count does not independently demonstrate that endotoxin levels are acceptable.

Where water is a critical material, its endotoxin specification and monitoring program should be defined according to its intended use and the relevant product requirements.

FireGene's Endotoxin Assay Water is intended for laboratory endotoxin testing workflows. Laboratories should confirm that the water meets the requirements of their specific procedure.

Active pharmaceutical ingredients and excipients

APIs and excipients can contribute to endotoxin risk depending on their source, manufacturing process, purification, and handling.

Potentially relevant materials include buffers, salts, stabilizers, surfactants, tonicity-adjusting agents, and other formulation ingredients.

The endotoxin profile of an ingredient may vary across suppliers or production lots. Supplier qualification, incoming-material specifications, and appropriate testing can help establish control over these differences.

However, an ingredient's endotoxin result does not automatically establish the endotoxin level of the finished formulation. The manufacturing process, additional ingredients, and handling conditions can also influence the final result.

Manufacturing equipment and contact surfaces

Preparation vessels, transfer systems, filling equipment, and product-contact components can introduce contamination if their cleaning and handling controls are inadequate.

Cleaning and sterilization should not be treated as interchangeable with endotoxin removal. A process that controls viable microorganisms may not necessarily remove or inactivate endotoxin to the extent required.

Where equipment cleaning or depyrogenation is part of the control strategy, the procedure should be appropriate for the equipment and supported by relevant validation or verification data.

Containers, closures, and packaging components

Containers and closures can be potential contributors to contamination. The risk depends on the component, its manufacturing process, its preparation, and how it is handled before use.

For products requiring controlled endotoxin levels, manufacturers should evaluate relevant components and define suitable supplier and incoming-material controls.

The final strategy should address the complete product-contact system rather than considering the formulation in isolation.

3. Why Inhalation Formulations Can Interfere With Endotoxin Testing

Bacterial endotoxin tests depend on a measurable reaction between endotoxin and the assay reagent. Certain sample properties can alter that reaction or interfere with the measurement.

A result is meaningful only when the selected method has demonstrated suitability for the specific sample under the intended conditions.

pH and buffer composition

Endotoxin assay reactions operate under defined conditions. A sample with an unsuitable pH or a high concentration of certain buffer components may inhibit or enhance the reaction.

This is relevant when testing concentrated formulations, buffered solutions, or samples prepared using extraction procedures.

Dilution may reduce the concentration of interfering components, but it also reduces the endotoxin concentration presented to the assay. A suitable dilution must therefore balance matrix compatibility with the required analytical sensitivity.

Preservatives and surfactants

Some inhalation formulations contain preservatives or surfactants to support product stability or other formulation requirements.

Depending on the compound and concentration, these ingredients may affect assay performance or interact with endotoxin. The direction and magnitude of the effect cannot be assumed without testing.

If a sample shows poor recovery, laboratories should review the formulation composition and evaluate whether a specific ingredient may be contributing to interference.

Suspended particles and turbidity

Suspensions and particulate-containing samples may present challenges for photometric assays.

In a kinetic chromogenic method, the analytical response is measured through changes in absorbance over time. Sample turbidity, color, or other optical properties may affect the measurement.

This does not mean that all suspensions are unsuitable for photometric testing. It means that the laboratory should demonstrate that the sample preparation and assay conditions provide reliable results.

Viscosity and sample handling

Viscous samples can be difficult to pipette accurately and consistently. Incomplete mixing or inconsistent aliquoting may result in variable sample concentrations.

The resulting variation can be mistaken for analytical interference or a change in endotoxin content.

A controlled sample preparation procedure should specify mixing, pipetting, dilution, and handling steps in sufficient detail to support reproducibility.

4. Selecting an Appropriate Endotoxin Test Method

The most suitable test method depends on the product, the analytical objective, the required sensitivity, and the relevant regulatory framework.

Gel-clot endotoxin testing

The gel-clot method provides a qualitative endpoint based on the formation of a firm gel under specified conditions.

It may be appropriate for certain limit-testing applications when the sample is compatible with the method and the required sensitivity can be achieved.

For inhalation formulations, laboratories should assess whether pH, preservatives, surfactants, or other components affect the reaction.

FireGene's Gel-Clot Endotoxin Test Kit offers a gel-clot approach for suitable laboratory applications. The kit's sensitivity and instructions should be evaluated against the intended test conditions.

Kinetic chromogenic endotoxin testing

Kinetic chromogenic assays measure color development over time and use the response to estimate endotoxin concentration against a standard curve.

This approach can provide quantitative data useful for method development, formulation comparisons, and trend analysis.

However, quantitative output does not guarantee that the result is valid. A sample may still interfere with the assay through optical effects, inhibition, enhancement, or unsuitable preparation conditions.

FireGene's Kinetic Chromogenic Endotoxin Test Kit is a microplate-based quantitative assay with a listed 0.005–10 EU/mL range and 405 nm absorbance detection. Laboratories should verify compatibility with their reader, sample matrix, and intended procedure.

Recombinant reagent methods

Recombinant reagent methods provide alternatives to conventional animal-derived lysate reagents. Their suitability depends on the specific reagent system, assay design, sample matrix, and applicable requirements.

In March 2026, the FDA revised its Pyrogen and Endotoxins Testing: Questions and Answers guidance to reflect a broader scope of recombinant reagents. The agency emphasizes that users should verify that the selected assay is suitable for its intended purpose.

The relevant principle applies regardless of reagent type: the method must be shown to work reliably with the material being tested.

For official context, see the FDA's Pyrogen and Endotoxins Testing: Questions and Answers.

5. Method Suitability and Positive Product Control Recovery

Positive product control (PPC) recovery is an important tool for evaluating whether a sample matrix interferes with an endotoxin assay.

In a typical PPC experiment, a known amount of endotoxin is added to the sample. The spiked sample is then tested alongside the appropriate controls. The measured response is compared with the expected response to determine whether the matrix suppresses or enhances detection.

For many bacterial endotoxin test procedures, 50%–200% recovery is a commonly used acceptance range. The applicable compendial procedure, validated method, and intended use should determine the actual criteria for a particular test.

Interpreting low recovery

Low recovery may indicate inhibition or reduced detectability under the test conditions.

Potential causes include:

• Unsuitable pH

• Incompatible formulation components

• Excessive concentrations of certain excipients

• Inadequate sample preparation

• Endotoxin interactions with the matrix

• Unsuitable storage or hold conditions

A low result should not automatically be interpreted as evidence that the sample contains little endotoxin.

Interpreting high recovery

High recovery may indicate enhancement or another matrix-related effect that produces a stronger response than expected.

The laboratory should investigate whether the sample composition, dilution, or assay conditions contribute to the result.

A practical method-suitability sequence

1. Select a representative sample.

2. Define the proposed sample preparation and dilution.

3. Include appropriate standards and negative controls.

4. Prepare the PPC using the established procedure.

5. Evaluate recovery against predefined acceptance criteria.

6. Investigate unacceptable recovery before relying on the sample result.

7. Confirm the revised procedure under the intended conditions.

FireGene's Control Standard Endotoxin (CSE) can support appropriate standard and control workflows when used according to its instructions.

6. Sample Preparation for Solutions, Suspensions, and Powders

Sample preparation is a critical part of the analytical method. It should provide a representative sample while preserving the ability to detect endotoxin.

Aqueous solutions

For a solution, the laboratory should establish whether direct testing is appropriate or whether dilution is needed to reduce interference.

The procedure should define the sample volume, mixing requirements, dilution medium, and time between preparation and testing.

If the formulation contains preservatives, surfactants, or concentrated buffers, method suitability should be demonstrated under the proposed conditions.

Suspensions

For suspensions, the laboratory should consider whether the sample must be mixed before aliquoting and how to obtain a representative portion.

The procedure should avoid uncontrolled settling or inconsistent sampling. If an extraction or other preparation step is needed, its effect on endotoxin recovery should be evaluated.

Dry powders

Dry powder products may require extraction or dispersion before testing. The extraction medium, extraction ratio, mixing procedure, and extraction time can all influence the resulting sample.

The laboratory should establish that the procedure provides appropriate recovery and does not introduce unacceptable interference.

A negative result from an unsuitable extraction procedure may not provide meaningful evidence about the endotoxin content of the original material.

7. Dilution Strategy and Maximum Valid Dilution

Dilution is often used to reduce interference, but it must be scientifically justified.

The maximum valid dilution (MVD) is the greatest dilution permitted under the applicable bacterial endotoxin testing framework while maintaining the ability to detect endotoxin at the relevant limit.

The appropriate calculation depends on the applicable endotoxin limit, product basis, and assay sensitivity. It should not be assumed that a limit or dilution strategy established for an injectable product automatically applies to an inhalation product.

A practical development workflow may include:

Initial Sample Assessment → Dilution Series → PPC Recovery → MVD Evaluation → Confirmatory Testing

The selected dilution should reduce interference sufficiently while preserving the ability to detect endotoxin at the required level.

Excessive dilution can produce an apparently low result simply because the endotoxin concentration falls below the method's useful detection range.

If acceptable recovery cannot be achieved within the permitted dilution, the laboratory should investigate other scientifically justified sample preparation options or evaluate a different suitable method.

8. Endotoxin Testing Is Not the Same as Sterility or Bioburden Testing

Endotoxin testing, sterility testing, and bioburden testing answer different questions.

• Endotoxin testing evaluates endotoxin activity or concentration under the conditions of the selected method.

• Sterility testing evaluates whether viable microorganisms are detected under the specified test conditions.

• Bioburden testing measures viable microorganisms in a material or process sample.

These tests are complementary rather than interchangeable.

A product may have a low microbial count while still containing endotoxin. Likewise, a negative endotoxin test does not demonstrate that a product is sterile.

A robust quality strategy should identify which attributes need to be controlled at each stage and establish suitable testing or process controls accordingly.

9. Building a Risk-Based Endotoxin Control Strategy

A practical endotoxin-control program connects raw-material oversight, manufacturing controls, analytical testing, and ongoing review.

Incoming materials

Evaluate supplier history, material source, manufacturing process, and the role of each ingredient in the final formulation.

For higher-risk materials, appropriate specifications and lot-specific data can support incoming-material decisions.

Water and equipment

Establish suitable controls for water systems, preparation vessels, transfer systems, and product-contact equipment.

Cleaning, sterilization, and depyrogenation procedures should be evaluated according to their specific purpose. A sterilization step should not be assumed to provide adequate endotoxin removal.

In-process monitoring

Where justified by process risk, testing selected intermediates can help identify potential contamination sources and evaluate the effectiveness of control measures.

Sampling locations should be chosen to answer specific questions about the process rather than simply increasing the number of tests.

Finished-product testing

Finished-product testing should follow the product's applicable specifications and established procedures. The test method must be suitable for the formulation and the intended analytical purpose.

Acceptance criteria should be scientifically justified and aligned with applicable regulatory expectations. A universal endotoxin limit should not be assigned to all inhalation products.

Trending and investigations

Reviewing results across batches, suppliers, and manufacturing periods may reveal patterns that are not apparent from individual results.

Unexpected results should be investigated systematically. Potential causes include contamination, sampling variation, matrix interference, reagent performance, and handling differences.

Retesting should follow the laboratory's established procedures and should not replace a documented investigation.

10. Common Mistakes in Inhalation Product Endotoxin Testing

Applying injectable limits without justification

Inhalation products differ from injectable products in route of administration, formulation, and delivery. Requirements should be established for the specific product rather than copied automatically from another dosage form.

Assuming a clear solution is interference-free

Visual clarity does not demonstrate assay compatibility. Chemical components can affect endotoxin detection even when a sample appears transparent.

Ignoring suspension homogeneity

If a suspension is not sampled consistently, measured results may vary because of differences in the material collected rather than changes in endotoxin concentration.

Using dilution without checking sensitivity

Dilution may improve recovery but can also reduce endotoxin concentration below the method's useful range. MVD and the relevant limit must be considered.

Treating a passing PPC as proof of every condition

PPC recovery supports method suitability under the tested conditions. It does not automatically establish suitability for different formulations, concentrations, sample preparation procedures, or hold times.

Relying on microbial testing alone

Microbiological results do not independently establish endotoxin levels. Each test should be interpreted according to the attribute it measures.

11. Regulatory Considerations for Inhalation Products

Regulatory expectations depend on the product, its intended use, and the applicable jurisdiction.

The FDA's guidance on Nasal Spray and Inhalation Solution, Suspension, and Spray Drug Products—Chemistry, Manufacturing, and Controls Documentation describes CMC considerations for specified nasal and inhalation dosage forms. It should be read within its stated scope; it does not cover every inhalation platform.

The FDA's March 2026 Pyrogen and Endotoxins Testing: Questions and Answers provides broader context for bacterial endotoxin and pyrogen testing, including gel-clot, photometric, and kinetic approaches and the use of recombinant reagents.

These documents do not establish one universal endotoxin specification for all inhalation products. Manufacturers should determine the applicable requirements using product-specific information, relevant compendial provisions, and regulatory advice where needed.

12. A Practical Checklist for Reliable Testing

Before establishing or updating an endotoxin testing procedure for an inhalation product, consider the following:

• Product type: Is the material a solution, suspension, aerosol-related formulation, or powder?

• Contamination risks: Have water, raw materials, equipment, and packaging components been assessed?

• Method selection: Is the assay appropriate for the sample and required analytical sensitivity?

• Matrix compatibility: Have potential effects from buffers, preservatives, surfactants, particles, or other excipients been evaluated?

• Sample preparation: Does the procedure provide a representative sample?

• PPC recovery: Has recovery been demonstrated under the intended conditions?

• Dilution: Does the selected dilution remain within the applicable MVD?

• Controls: Are standards, negative controls, water, and consumables appropriate?

• Documentation: Are sample preparation, reagent lots, instrument conditions, and results traceable?

• Review: Are results evaluated for unexpected changes and recurring trends?

This checklist is a starting point for method development and quality planning, not a replacement for a validated procedure or product-specific regulatory requirements.

Conclusion: Reliable Endotoxin Testing Starts With Product-Specific Method Suitability

Endotoxin testing for inhalation products requires a clear understanding of the formulation, manufacturing process, and intended use.

Water systems, raw materials, equipment, and packaging components can all contribute to contamination risk. At the same time, formulation ingredients, suspended particles, sample preparation, and dilution can influence the analytical result.

A robust strategy combines risk-based contamination control with an appropriate test method, representative sampling, positive product control recovery, and scientifically justified dilution.

Most importantly, the endotoxin limit and testing approach must be appropriate for the specific product. Injectable-product requirements should not be transferred automatically to inhalation formulations without justification.

For laboratories developing or evaluating inhalation product testing procedures, the central objective is straightforward: demonstrate that the chosen method can produce reliable, interpretable results for the actual sample under the intended conditions.

Explore FireGene endotoxin testing solutions:
https://firegene.com/collections/endotoxin-assay-reagents-and-kits

References

• U.S. Food and Drug Administration. Pyrogen and Endotoxins Testing: Questions and Answers, March 2026.

• U.S. Food and Drug Administration. Nasal Spray and Inhalation Solution, Suspension, and Spray Drug Products—Chemistry, Manufacturing, and Controls Documentation.

• European Medicines Agency. Guideline on the Pharmaceutical Quality of Inhalation and Nasal Products.